https://doi.org/10.55788/5bc6328a
Dr Yu-Hsiang Ling (Taipei General Veterans Hospital, Taiwan) and colleagues hypothesised that an increased arterial stiffness leading to a blood pressure surge and increased central pulsatile flow can impact the blood-brain barrier in patients with reversible cerebral vasoconstriction syndrome. They applied contrast-enhanced T2 fluid-attenuated inversion recovery imaging in patients with reversible cerebral vasoconstriction syndrome and healthy controls [1]. Arterial stiffness was assessed using carotid-femoral pulse wave velocity, augmentation index, and central blood pressure.
In total, 65 patients with reversible cerebral vasoconstriction syndrome and 65 age- and sex-matched healthy volunteers were included in the study. Of participants with reversible cerebral vasoconstriction syndrome, 50.8% presented with blood-brain barrier disruption. They also tended to have higher carotid-femoral pulse wave velocity values than healthy controls (P<0.001), suggesting increased central arterial stiffness. Furthermore, when assessing participants with blood-brain barrier disruption, values for carotid-femoral pulse wave velocity measurement and the augmentation index were significantly higher for patients with blood-brain barrier disruption than for those without disruption.
âWe confirmed that patients with reversible cerebral vasoconstriction syndrome had elevated central arterial stiffness, and we also confirmed its association with blood-brain barrier disruptionâ, said Dr Ling. âThis finding supports the conclusion that increased central arterial stiffness may play a pivotal role in the pathogenesis of blood-brain barrier disruption and probably the overall pathophysiology of reversible cerebral vasoconstriction syndrome.â
- Ling YH, et al. Increased systemic arterial stiffness is associated with blood-brain barrier disruption in reversible cerebral vasoconstriction syndrome. 18th European Headache Congress, 4â7 December 2024, Rotterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« AI can enhance migraine diagnosis using easy-to-measure clinical data Next Article
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura »
« AI can enhance migraine diagnosis using easy-to-measure clinical data Next Article
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura »
Table of Contents: EHC 2024
Featured articles
More education on migraine features is needed
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Understanding Migraine Mechanisms
The locus coeruleus is involved in processing pain in migraine
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome
Diagnostic and Predictive Tools
AI can enhance migraine diagnosis using easy-to-measure clinical data
New tool adequately captures multiple pain types in trigeminal neuralgia
MRI analyses suggest that migraine is not associated with altered brain white matter
More education on migraine features is needed
Treatment Innovations
PACAP-targeting therapies: a future option for migraine?
Rapid complete responses with atogepant
Cabergoline is a potential add-on treatment option in patients with migraine
Nitroglycerin-induced migraine targetable by different agents
Rimegepant reduces migraine symptoms through 1 year of treatment
Fremanezumab is a treatment option for paediatric patients with episodic migraine
What brain changes are associated with fremanezumab treatment success?
Preventative Therapies in Real-world Context
Low discontinuation rates with preventative galcanezumab in a real-world setting
Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders
Biofeedback training can reduce affected days in episodic migraine
Virtual reality interventions can reduce pain perception of chronic headache
Risk Factors and Long-term Management
Can predisposing factors be targeted to reduce new migraine incidence?
Active migraine comes at a high cost in Spain
Many patients, including non-responders, prefer triptans over non-headache-specific medication
Systemic Conditions and Migraine
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Related Articles
January 5, 2023
Atogepant for the preventive treatment of chronic migraine
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
